Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

MLA

Bouchart, Christelle, et al. “Isotoxic High-Dose Stereotactic Body Radiotherapy Integrated in a Total Multimodal Neoadjuvant Strategy for the Treatment of Localized Pancreatic Ductal Adenocarcinoma.” Therapeutic Advances in Medical Oncology, Oct. 2021, pp. 1–15. EBSCOhost, https://doi.org/10.1177/17588359211045860.

APA

Bouchart, C., Engelholm, J.-L., Closset, J., Navez, J., Loi, P., Gökburun, Y., De Grez, T., Mans, L., Hendlisz, A., Bali, M. A., Eisendrath, P., Van Gestel, D., Hein, M., Moretti, L., & Van Laethem, J.-L. (2021). Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 1–15. https://doi.org/10.1177/17588359211045860

Chicago

Bouchart, Christelle, Jean-Luc Engelholm, Jean Closset, Julie Navez, Patrizia Loi, Yeter Gökburun, Thierry De Grez, et al. 2021. “Isotoxic High-Dose Stereotactic Body Radiotherapy Integrated in a Total Multimodal Neoadjuvant Strategy for the Treatment of Localized Pancreatic Ductal Adenocarcinoma.” Therapeutic Advances in Medical Oncology, October, 1–15. doi:10.1177/17588359211045860.